Antifungal combination therapy with voriconazole or amphotericin B and an echinocandin is often employed as primary or salvage therapy for management particularly of refractory aspergillosis. The pharmacodynamic interactions of amphotericin Band voriconazole-based combinations with the three echinocandins caspofungin, micafungin, and anidulafungin in the presence of serum were tested against 15 Aspergillus fumigatus complex, A. flavus complex, and A. terreus complex isolates to assess both their growth-inhibitory and fungicidal activities. The in vitro activity of each drug alone and in combination at a 1:1 fixed concentration ratio was tested with a broth microdilution colorimetric method, and interactions were assessed by isobolographic analysis. Synergy was found for all amphotericin B-and voriconazole-based combinations, with amphotericin B-based combinations showing strong inhibitory synergistic interactions (interaction indices of 0.20 to 0.52) and with voriconazole-based combinations demonstrating strong fungicidal synergistic interactions (interaction indices of 0.10 to 0.29) (P < 0.001). Drug-and species-specific differences were found, with caspofungin and the A. fumigatus complex exhibiting the weakest synergistic interactions. In the presence of serum, the synergistic interactions were reduced in the order (from largest to smallest decrease) micafungin > anidulafungin > caspofungin, and A. flavus complex > A. fumigatus complex > A. terreus complex, resulting in additive interactions, particularly for inhibitory activities of amphotericin B-echinocandin combinations and fungicidal activities of voriconazole-echinocandin combinations. Drug-and species-specific differences were found in the presence of serum for inhibitory activities of antifungal drugs, with the lowest interaction indices being observed for amphotericin B-caspofungin (median, 0.77) and for the A. terreus complex (median, 0.56). The present in vitro data showed that serum had a major impact on synergistic interactions of amphotericin B-echinocandin and voriconazole-echinocandin combinations, resulting in additive interactions and explaining the indifferent outcomes usually observed in vivo.
I
nvasive aspergillosis is a life-threatening disease in immunocompromised patients that is associated with high mortality rates, despite antifungal therapy (1) . Although voriconazole is the first choice for treatment of invasive aspergillosis, amphotericin B and echinocandins (mainly caspofungin) are also used to treat this infection (2, 3) . Alternatively, and in particular for refractory aspergillosis, antifungal combination therapy is often employed as primary or salvage therapy for the management of this infection, with the hope to improve monotherapy outcomes (4) (5) (6) . Among the most commonly used antifungal combination regimens is voriconazole or amphotericin B with an echinocandin given the potential for synergistic interactions because of the distinct mechanisms of action of these drugs: voriconazole and amphotericin B alter cell membrane function, whereas echinocandins alter cell wall function.
A few comparative clinical trials have assessed the efficacy of antifungal combinations as primary therapy for invasive aspergillosis and showed an insignificant advantage of voriconazole-echinocandin compared to voriconazole monotherapy (7, 8) and a favorable response of liposomal amphotericin B-echinocandin combination therapy compared to monotherapy with a higher dose of liposomal amphotericin B (9) . However, pharmacodynamic interactions in clinical trials may be obscured by confounding factors such as underlying disease, concomitant therapy, and toxicity and because combination regimens were compared with one of the two monotherapy regimens without taking into account the effect of the second drug. Most of the available information concerning the efficacy of antifungal combinational therapy comes from preclinical studies, with in vitro studies demonstrating mostly synergistic-to-additive/indifferent interactions (10) (11) (12) (13) (14) (15) and in vivo studies showing mostly no significant improvement compared to monotherapy (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
Although standardized antifungal susceptibility testing is now available (26, 27) , the information gleaned from in vitro susceptibility testing is characterized by limitations, as the MIC provides only a static measurement of the antimicrobial effect in a defined medium (28) . Biological fluids such as human serum and urine can have profound effects on antimicrobial pharmacodynamics (29, 30) , with numerous studies demonstrating that only the free or unbound fraction of drug is available for antimicrobial activity (31) . However, the MICs of antifungal drugs are usually increased in the presence of serum, but the increase cannot be predicted based on the free-drug concentrations (32) (33) (34) (35) (36) . We also recently investigated the effect of serum on antifungal drugs against Aspergillus spp., which showed a differential effect with increased activity of voriconazole and echinocandins (at supraminimum effective concentrations [MECs] ) and decreased activity of amphotericin B and echinocandins (at sub-MECs) in the presence of serum, which was not predicted by percent protein binding (37) . Although the impact of human serum on in vitro activities of single drugs has been investigated previously, the effect of serum on antifungal combinations is largely unknown.
Serum may influence the in vitro activity of antifungal drugs directly by decreasing the free fraction of drugs and indirectly by affecting fungal growth (38, 39) . Since antifungal agents are extensively bound to serum proteins at rates of 96% for caspofungin, 99.8% for micafungin (14) , ϳ99% for anidulafungin, ϳ60% for voriconazole, and Ͼ95% for amphotericin B (40), the impact of serum on the nature and/or magnitude of pharmacodynamic interactions is expected to be large. Given that MIC determinations in the presence of serum may be a better predictor of in vivo outcomes (33) , pharmacodynamic interactions in the presence of serum may be clinically relevant.
A comparative in vitro study assessing antifungal combinations of the three echinocandins with amphotericin B or voriconazole against different Aspergillus species is missing. Therefore, the aim of the present study was to characterize the pharmacodynamic interactions of amphotericin B-and voriconazole-based combinations with the three echinocandins caspofungin, micafungin, and anidulafungin in the presence of serum against Aspergillus fumigatus complex, A. flavus complex, and A. terreus complex isolates to assess both the growth-inhibitory and fungicidal activities of the combinations.
MATERIALS AND METHODS
Isolates and inoculum. Fifteen Aspergillus clinical isolates (5 Aspergillus fumigatus complex, 5 Aspergillus flavus complex, and 5 Aspergillus terreus complex isolates) were tested. Species were identified morphologically. Isolates were kept frozen in 10% glycerol at Ϫ70°C and revived by subculturing twice onto Sabouraud dextrose agar (SDA) plates containing chloramphenicol for 7 to 10 days at 35°C. Conidia were collected with a wet cotton swab and suspended in sterile normal saline containing 0.025% Tween 20. The conidial suspensions were adjusted by using a Neubauer counting chamber to 4 ϫ 10 4 conidia/ml, corresponding to 2 times the final inoculum in saline or human serum. The concentration and viability of each suspension were confirmed by culturing on SDA plates for 24 h at 35°C. Candida krusei (ATCC 6258), Candida parapsilosis (ATCC 22019), and Aspergillus fumigatus (ATCC MYA-3626) strains were used as quality control (QC) strains.
Growth medium and human serum. RPMI 1640 medium (with Lglutamine and without bicarbonate), buffered with 0.165 M 3-N-morpholinepropanesulfonic acid (MOPS) (AppliChem, Darmstadt, Germany) to pH 7.0, was used as the growth medium. Human serum was pooled from outpatients, heat inactivated at 56°C for 30 min, and stored at Ϫ70°C for 7 to 10 days until use.
Antifungal agents and drug dilutions. Stock solutions of pure powders were prepared in dimethyl sulfoxide (voriconazole, anidulafungin, and amphotericin B) or water (caspofungin and micafungin) and were stored at Ϫ70°C until use. Following the principles of CLSI document M38-A2 (27) , serial 2-fold dilutions at 2ϫ the final concentration were prepared in 8 wells containing 100 l of double-strength test medium (RPMI 1640 medium with MOPS) in 96-well flat-bottom microtitration plates (Costar 3596; Corning Inc., Antisel, Athens, Greece). The final concentrations of antifungal agents, after the addition of conidial inocula, ranged from 8 to 0.06 mg/liter. For combination studies, a 1:1 fixed concentration ratio design was followed, where 50 l of the first drug was combined with 50 l of the second drug at 4ϫ the final concentration, which ranged from 8 to 0.06 mg/liter for each drug. The 1:1 ratio was chosen in order to approximate the ratio of trough levels attained with standard dosing of antifungal drugs (41) .
XTT and menadione. XTT {2,3-bis[2-methoxy-4-nitro-5-(sulphenylamino)carbonyl]-2H-tetrazolium hydroxide} sodium salt (Applichem, Bioline, Athens, Greece) was dissolved in sterile distilled water before use. Menadione (Applichem, Bioline, Athens, Greece) was used as an electron-coupling agent and was initially dissolved in absolute ethanol at a concentration of 58 ϫ 10 Ϫ3 M. A working solution of 0.5 mg/ml of XTT with 31.25 ϫ 10 Ϫ6 ⌴ menadione was prepared in sterile distilled water. Susceptibility testing. The in vitro susceptibilities of all 15 Aspergillus isolates to amphotericin B, voriconazole, and all three echinocandins alone and in combination were tested according to the principles of the CLSI M38-A2 method, using standard medium without and with 50% (vol/vol) human serum. To achieve this, 100 l of conidial suspensions in sterile saline or in 100% human serum was inoculated into 100 l of double-strength growth medium containing 2-fold serial dilutions of antifungal drugs at 2ϫ (for drugs alone) or 4ϫ (for combinations) the final concentrations in 96-well flat-bottom microtitration plates. Plates were then incubated at 35°C for 48 h, and fungal growth in each well was quantified visually with the aid of a magnifying mirror and with the XTT methodology in order to assess growth-inhibitory and fungicidal activities, as described below, based on previously reported studies (42, 43) .
All experiments were performed in triplicates. The minimum effective concentrations (MECs) of caspofungin, micafungin, and anidulafungin were macroscopically and microscopically determined as the lowest drug concentration with prominent growth reduction and short, stubby, and aberrant hyphae, respectively, whereas the MIC of amphotericin B and voriconazole was determined as the lowest drug concentration showing complete inhibition of growth (27) .
Inhibitory activity. Inhibitory activities of antifungal drugs were assessed by using the XTT methodology, as previously described (44, 45) . Briefly, after 48 h of incubation, 50 l of the XTT-menadione working solution was added to each well, yielding final concentrations of 0.1 mg/ml of XTT and 6.25 ϫ 10 Ϫ6 M menadione. Subsequently, the microtitration plates were incubated at 35°C for 2 h. Plates were shaken for 1 to 2 min (Wallac Plate Shake 1296-004; Wallac Oy, Turku, Finland) until the formazan derivatives were dissolved, and the color absorbance was measured spectrophotometrically at 450 nm, with a reference wavelength at 630 nm (Infinite F200; Tecan, Austria).
The background absorbance (A background ) (absorbance of conidiumfree plates processed in the same way as the inoculated plates) was subtracted, and the percentage of growth at each drug concentration (A well ) with and without serum was calculated based on the absorbance of the drug-free control (A drug-free ) with and without serum, respectively, as 100% ϫ (A well Ϫ A well background )/(A drug-free well Ϫ A drug-free well background ).
Fungicidal activity. After determination of growth-inhibitory activities, fungicidal activities of all antifungal combinations were assessed as previously described (43) . Briefly, the contents of all clear wells and the well at 0.5ϫ MIC were carefully aspirated and washed twice with 200 l of normal saline prewarmed at 35°C. After gentle agitation, 200 l of fresh growth medium was added to each well, and microtitration plates were incubated at 35°C for 24 h. Subsequently, 50 l of the XTT-menadione working solution was added to each well, and the wells were further incubated at 35°C for 2 h. After plates were shaken for 1 to 2 min, the color absorbance was measured spectrophotometrically at 450 nm with a reference wavelength at 630 nm (Infinite F200; Tecan, Austria), and the percentage of fungal growth was calculated as described above.
Growth endpoint determination. The percentages of fungal growth estimated from the growth-inhibitory and fungicidal experiments were further analyzed with nonlinear regression analysis based on the sigmoidal maximum effect (E max ) model with a variable slope, described by the
, where E max is maximal growth at the drug-free control for the growth-inhibitory exper-iments and the maximal XTT absorbance for the fungicidal experiments, E min is the minimal growth observed at high drug concentrations, C is the drug concentration, IC 50 (50% inhibitory concentration) is the drug concentration corresponding to 50% of the value of E max minus E min , and n is the hill slope (GraphPad Prism 5.0 software; GraphPad, San Diego, CA). Based on this equation, the near-maximum inhibitory concentration (IC 90 ) and near-maximum fungicidal concentration (FC 90 ) were calculated as the concentration corresponding to 10% growth (E max Ϫ E min ) from the growth-inhibitory and fungicidal experiments, respectively.
As previously shown, the MICs of amphotericin B and voriconazole and the MECs of echinocandins correspond to the lowest drug concentration with 10% (IC 90 ) and 50% (IC 50 ) of growth, respectively, by the XTT methodology (44, 45) , whereas the minimal fungicidal concentration (MFC) of amphotericin B and voriconazole corresponds to the lowest drug concentration with 10% of growth (FC 90 ) by the XTT methodology (43) .
Interaction analysis. Pharmacodynamic interactions based on inhibitory and fungicidal activities were assessed at 10% (IC 90 and FC 90 ) and 50% (IC 50 and FC 50 ) growth endpoints by Lowe additivity-based isobolographic analysis, as previously described (46) . Briefly, for the combination of amphotericin B (AMB) or voriconazole (VOR) with each echinocandin (ECH), the interaction index (Ii) was calculated for each X% growth endpoint based on the equation Ii ϭ C X,AMB/VORcomb / IC X,AMB/VORalone ϩ C X,ECHcomb /IC X,ECHalone , where IC X,AMB/VORalone and IC X,ECHalone are the concentrations of amphotericin B or voriconazole and the echinocandin alone and C X,AMB/VORcomb and C X,ECHcomb are the concentrations of amphotericin B or voriconazole and the echinocandin in combination corresponding to the X% (10% or 50%) growth endpoint, respectively. The IC X,AMB/VORalone and IC X,ECHalone values were determined by E max modeling of the single-drug concentration-effect curves from all three replicates. Whenever echinocandins did not exhibit a 10% growth endpoint (e.g., in the absence of serum) at the concentrations tested, IC X,ECHalone was considered the next-highest 2-fold concentration tested, i.e., 16 mg/liter. This approximation has a minimal impact on the Ii values, which are determined mainly by the first term of the interaction index equation C X,AMB/VORcomb /IC X,AMB/VORalone , since the second term, C X,ECHcomb /IC X,ECHalone , is much smaller than the first term because C X,ECHcomb Ͻ Ͻ IC X,ECHalone. C X,AMB/VORcomb and C X,ECHcomb were determined by E max modeling of the concentration-effect curves of the 1:1 fixed-ratio combinations from all three replicates, where the equation C TOT ϭ C X,AMB/VORalone ϩ C X,ECHalone (where C TOT is the total concentration) was used as the independent variable for the regression analysis (47) . Individual C X,AMB/VOR and C X,ECH values were calculated from the C TOT value obtained from regression analysis as C TOT /2, since both drugs in the 1:1 fixed-ratio combination are at equal concentrations. Synergy and antagonism were concluded when the Ii was statistically significantly Ͻ1 and Ͼ1.25, respectively, based on a t test, as previously described (48) . In any other case, additivity was concluded.
In order to compare the interactions (i) among the three echinocandins for amphotericin B-based and voriconazole-based combinations, (ii) between amphotericin B and voriconazole for each echinocandin, (iii) of each combination with and without serum, and (iv) of all combinations among the three species, the Ii values were analyzed by repeated-measures analysis of variance (ANOVA) followed by Tukey's multiple-comparison test (GraphPad Prism 5.0). A P value of Ͻ0.05 (two tailed) was considered statistically significant.
RESULTS

Concentration
-effect relationship for single drugs. The MICs of the QC strains were within the reference ranges (27) . In particular, for the A. fumigatus QC strain, the CLSI and XTT MICs, MECs, and MFCs of amphotericin B, voriconazole, and echinocandins were within previously determined ranges (42, 43) . The MECs of caspofungin, micafungin, and anidulafungin against all Aspergillus isolates were 0.5 to 1 mg/liter, 0.06 to 0.12 mg/liter, and 0.03 to 0.06 mg/liter, respectively, and the MICs of amphotericin B and voriconazole were 0.5 to 4 mg/liter and 0.25 to 2 mg/liter, respectively. Similarly, the XTT IC 50 s of caspofungin, micafungin, and anidulafungin were 0.07 to 1 mg/liter, 0.01 to 0.09 mg/liter, and 0.01 to 0.06 mg/liter, respectively (data not shown), and the XTT IC 90 s of amphotericin B and voriconazole were 0.71 to 2.99 mg/ liter and 0.14 to 5.28 mg/liter, respectively, for all strains and species (Table 1) .
Pharmacodynamic interactions of combinations. The results of the interaction analysis of amphotericin B-and voriconazolebased combinations with the three echinocandins are shown in Table 1 for the inhibitory and in Table 2 for fungicidal activities for the 10% growth endpoint. Similar results but weaker interactions were found for both inhibitory and fungicidal effects for the 50% growth endpoint (data not shown).
Pharmacodynamic interactions in the absence of serum. Synergy was found for all amphotericin B-and voriconazolebased combinations for both inhibitory and fungicidal activities (Ii Ͻ 1; P Ͻ 0.05) ( Tables 1 and 2 ). Overall, voriconazole-based combinations showed 2.13-to 7.4-fold-stronger synergistic fungicidal interactions than inhibitory interactions, particularly with micafungin and anidulafungin (P Ͻ 0.001). The synergistic interactions of amphotericin B-based echinocandin combinations (Ii values of 0.20 to 0.52) were stronger than those of the voriconazole-based echinocandin combinations (0.43 to 0.84) for inhibitory effects, whereas the opposite was observed for fungicidal effects (0.14 to 0.58 and 0.10 to 0.29, respectively; P Ͻ 0.001) ( Tables  1 and 2 ).
Significant differences were found among the three echinocandins, with caspofungin-based combinations showing weaker synergy than micafungin-and anidulafungin-based combinations for inhibitory activity (median Ii of 0.34 versus 0.26 versus 0.24 for amphotericin B and 0.60 versus 0.49 versus 0.55 for voriconazole, respectively) and fungicidal activity (0.31 versus 0.26 versus 0.19 and 0.37 versus 0.14 versus 0.12, respectively) (P Ͻ 0.0001). Among the three species, significant differences were found only for inhibitory effects, with weaker synergy observed for A. fumigatus complex (median Ii ϭ 0.60) than for A. flavus complex (median Ii ϭ 0.35) and A. terreus complex (median Ii ϭ 0.44) isolates (P ϭ 0.0005).
Pharmacodynamic interactions in the presence of serum. The interaction indices of all amphotericin B-and voriconazolebased echinocandin combinations increased in the presence of serum, reversing the synergy detected in the absence of serum to additivity in the presence of serum for inhibitory activities (P Ͻ 0.001 by ANOVA) ( Table 1 ). This phenomenon was also observed for the fungicidal activities of voriconazole-echinocandin combinations. Overall, the largest increase in Ii values for inhibitory effects in the presence of serum was found for amphotericin Bechinocandin (average increase of 3.3-fold) compared to voriconazole-echinocandin (average increase of 2-fold) combinations and among echinocandin combinations for micafungin-based (3.6-fold) and anidulafungin-based (2.9-fold) combinations compared to caspofungin-based (2-fold) combinations (P Ͻ 0.0001) ( Table 1) . Of note, the increase in Ii values for inhibitory effects in the presence of serum resulted in antagonism for the amphotericin B-micafungin combination against the A. flavus complex. Regarding the fungicidal effects, the largest increase in Ii values was found for voriconazole-echinocandin combinations and particularly with micafungin (2.5-to 8.1-fold) and anidula-fungin (1.7-to 5.5-fold) (P Ͻ 0.0001) ( Table 2 ). Significant differences among the three Aspergillus species were found only for growth-inhibitory effects, with the A. terreus complex demonstrating the smallest increase of Ii values in the presence of serum (mean increase, 1.7-fold) compared to the A. fumigatus complex (4.4-fold) and A. flavus complex (6.7-fold) (P ϭ 0.011).
Drug-specific differences were found in the presence of serum, based on inhibitory effects where overall amphotericin B-caspofungin showed the lowest Ii values (median Ii ϭ 0.77) and amphotericin B-micafungin showed the highest Ii values (median Ii ϭ 2.19) among all combinations; no significant differences were 
DISCUSSION
Synergy in vitro was found in the absence of serum for all amphotericin B-and voriconazole-echinocandin combinations, with amphotericin B-based combinations exhibiting strong inhibitory and voriconazole-based combinations exhibiting strong fungicidal synergistic interactions. Drug-and species-specific differences were found, with caspofungin and the A. fumigatus complex exhibiting the weakest synergistic interactions. In the presence of serum, the synergistic interactions were reduced, resulting in additive interactions, particularly for inhibitory effects. The largest decrease of synergistic interactions was observed for inhibitory activities of amphotericin B-echinocandin combinations and for fungicidal activities of voriconazole-echinocandin combinations. Among echinocandins and Aspergillus species, the synergistic interactions were reduced in the presence of serum in the following order, from largest to smallest decrease: micafungin Ͼ anidulafungin Ͼ caspofungin, and A. flavus complex Ͼ A. fumigatus complex Ͼ A. terreus complex. In the presence of serum, most combinations were additive based on inhibitory effects, with amphotericin B-caspofungin having lower interaction indices and amphotericin B-micafungin having the highest, whereas based on fungicidal effects, most combinations remained synergistic, with no significant differences among them. Among Aspergillus species, the weakest synergistic interactions were found with the A. flavus complex for both inhibitory and fungicidal effects. In most previously reported studies, amphotericin B or voriconazole combinations with an echinocandin were tested with a microdilution assays and assessed based on the fractional inhibitory concentration (FIC) indices, resulting in additive/indifferent interactions (FIC indices of 0.5 to 4) and a few times in synergistic interactions (FIC indices of Ͻ0.5) but never in antagonistic interactions (FIC indices of Ͼ4) (10, (49) (50) (51) (52) . The discrepancy with the findings of the present study, where most combinations were synergistic, was due to the different cutoffs used to assess in vitro interactions. Although the FIC index range of 0.5 to 4 was proposed to define additive/indifferent interactions (53), this range is very broad to detect significant pharmacodynamic interactions, and combinations with FIC indices of Ͻ1 and Ͼ1.25 were found in vivo to be synergistic and antagonistic, respectively (48, 54, 55) . These cutoffs may also be reliable for voriconazole-echinocandin combinations, since it was previously found that the voriconazole-anidulafungin combination prolonged survival compared to monotherapy in vitro when the FIC index was 0.5 to 1 (16) . By using a cutoff value of 1, most of the in vitro combinations were synergistic rather than additive, as found in the present study (15, 56) .
Another source of discrepancy may be the different growth endpoints for amphotericin B or voriconazole (MIC or complete growth inhibition) and echinocandins (MEC or prominent growth inhibition) (11) . FIC indices should always be calculated based on isoeffective concentrations, i.e., drug concentrations that produce the same effect at a certain level, e.g., 10% growth inhibition, fungicidal action, or metabolic inhibition (57) . Thus, the MIC, which corresponds to complete (100%) growth inhibition, and the MEC, which corresponds to lowest concentration with aberrant hyphae and correlates with prominent (50%) growth inhibition, are not isoeffective (45) . Using the same endpoint for both drugs alone and in combination overcomes the dilemma of which endpoint should be used for the combination of amphotericin B or voriconazole and an echinocandin. In the present study, pharmacodynamic interactions were assessed based on two different effects, i.e., inhibitory and fungicidal effects, at two different effect levels (10% and 50%), with stronger interactions observed at the 10% level, as also found previously (58) . Effective concentrations were calculated by nonlinear regression analysis, providing greater precision and accuracy than the approximate and variable visually determined MICs and MECs.
The synergistic interaction between amphotericin B or voriconazole and an echinocandin could be explained by the different mechanism of action, targeting the cell membrane and wall, respectively. The reduction of synergy in the presence of serum could be explained by the effect of serum on each drug alone and in combination. Serum increased the ICs and FCs of amphotericin B and amphotericin B-echinocandin, particularly for fungicidal effects. In contrast, voriconazole ICs and FCs were reduced in the presence of serum, whereas voriconazole-echinocandin concentrations increased or remained the same. The most prominent effect of serum that led to a reduction of synergistic interactions was the marked decrease of ICs of echinocandins observed in the presence of serum, resulting in higher interaction indices. The reduction of synergistic fungicidal interactions was due to a higher increase of the total concentration of combinations in the presence of serum than the increase of the concentrations of the drugs alone. This differential effect may be related to the molecular interactions for binding sites, since amphotericin B, voriconazole, and echinocandins are highly bound to albumin (41) . The increase of ICs and FCs could be due to protein binding, decreasing the amount of free drug available to exert the inhibitory or fungicidal effect. The reduction of echinocandin ICs may be due to the cell wall stress response pathways of glycerol, calcineurin, and chitin, which are synergistically inhibited by serum and echinocandins in a way similar to the synergistic interaction between the chitin synthase inhibitor nikkomycin Z or the calcineurin inhibitors tacrolimus and cyclosporine and echinocandins (59, 60) .
Most in vivo studies of amphotericin B-or voriconazole-echinocandin combinations showed an indifferent outcome (i.e., combination therapy outcome similar to that of monotherapy) (11, 16, 17, 19-22, 25, 61, 62) , and few studies demonstrated an enhanced outcome compared to that with monotherapy (18, 23, 24, 63) . However, in most of the latter studies, single doses of combined drugs were used, making the determination of synergistic interactions impossible, since both additive and synergistic interactions would have an effect greater than the effect of each drug alone. In one study, where synergy was found between voriconazole and anidulafungin in mice dosed once daily, the ratio of voriconazole and anidulafungin trough levels was Ͻ1:8, rarely observed in humans with twice-a-day dosing of voriconazole (63) . This in agreement with a recent clinical trial of antifungal combination therapy with the same drugs, where no significant improvement was found, as observed in the present study in the presence of serum (8) . Finally, the unexpected antagonism between micafungin and amphotericin B in the presence of serum against the A. flavus complex is in line with the in vivo antagonism when micafungin was sequentially combined with a low dose of liposomal amphotericin B and requires further investigation to elucidate whether this effect is because of immunological and/or pharmacodynamic interactions (64) . In vivo extrapolation of in vitro data would require experiments with multiple doses, determination of dose-response curves of drugs alone and in combination, and pharmacokinetic data correlating in vitro concentrations with in vivo drug levels.
In conclusion, the present in vitro data showed that serum had a major impact on synergistic interactions of amphotericin B-and voriconazole-echinocandin combinations, resulting in additive interactions and explaining the indifferent outcomes usually observed in vivo.
